A Survey of FDG- and Amyloid-PET Imaging in Dementia and GRADE Analysis
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
PET based tools can improve the early diagnosis of Alzheimer’s disease (AD) and differential diagnosis of dementia. The importance of identifying individuals at risk of developing dementia among people with subjective cognitive complaints or mild cognitive impairment has clinical, social, and therapeutic implications. Within the two major classes of AD biomarkers currently identified, that is, markers of pathology and neurodegeneration, amyloid- and FDG-PET imaging represent decisive tools for their measurement. As a consequence, the PET tools have been recognized to be of crucial value in the recent guidelines for the early diagnosis of AD and other dementia conditions. The references based recommendations, however, include large PET imaging literature based on visual methods that greatly reduces sensitivity and specificity and lacks a clear cut-off between normal and pathological findings. PET imaging can be assessed using parametric or voxel-wise analyses by comparing the subject’s scan with a normative data set, significantly increasing the diagnostic accuracy. This paper is a survey of the relevant literature on FDG and amyloid-PET imaging aimed at providing the value of quantification for the early and differential diagnosis of AD. This allowed a meta-analysis and GRADE analysis revealing high values for PET imaging that might be useful in considering recommendations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814 · cited 2×
“The basic concept is that FDG-PET estimates glucose consumption at the synaptic-astrocyte level [90] thus picking-up very early changes already detectable even in asymptomatic subjects at high risk for AD [113, 114].”
BackgroundGRADE guidelines: 7. Rating the quality of evidence—inconsistency
Guyatt, G. H., Oxman, A. D., Kunz, R., Woodcock, J., Brozek, J., Helfand, M., Alonso-Coello, P., Glasziou, P., Jaeschke, R., Akl, E. A., et al. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2011.03.017 · Cited by 2,320
Revising the definition of Alzheimer's disease: a new lexicon
Dubois, B., Feldman, H. H., Jacova, C., Cummings, J. L., DeKosky, S. T., Barberger-Gateau, P., Delacourte, A., Frisoni, G., Fox, N. C., Galasko, D., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70223-4 · Cited by 1,869 · cited 4×
“In fact, both the “Dubois” [5, 9] and the NIA-AA [6, 8] new diagnostic criteria have included FDG-PET as a valid tool for biomarker measure of neurodegeneration, by showing specific metabolic changes that precede atrophy as detected with MRI.”
BackgroundMethodInfluentialSelf-citationGrading quality of evidence and strength of recommendations for diagnostic tests and strategies
Schünemann, H. J., Oxman, A. D., Brozek, J., Glasziou, P., Jaeschke, R., Vist, G. E., Williams, J. W., Kunz, R., Craig, J., Montori, V. M., et al. (2008) · BMJ · doi:10.1136/bmj.39500.677199.ae · Cited by 1,782
Hansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70355-6 · Cited by 1,700
Knopman, D. S., DeKosky, S. T., Cummings, J. L., Chui, H., Corey–Bloom, J., Relkin, N., Small, G. W., Miller, B., & Stevens, J. C. (2001) · Neurology · doi:10.1212/wnl.56.9.1143 · Cited by 1,410
Use of Florbetapir-PET for Imaging β-Amyloid Pathology
Clark, C. M. (2011) · JAMA · doi:10.1001/jama.2010.2008 · Cited by 1,117
[ 11 C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease
Mintun, M. A., LaRossa, G. N., Sheline, Y. I., Dence, C. S., Lee, S. Y., Mach, R. H., Klunk, W. E., Mathis, C. A., DeKosky, S. T., & Morris, J. C. (2006) · Neurology · doi:10.1212/01.wnl.0000228230.26044.a4 · Cited by 1,036 · cited 1×
“A paper from Mintun and colleagues [126] focused on this aspect by using”
Method(1995) · PubMed Central · doi:10.2967/jnumed.120.252510a · Cited by 996
Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging
Rowe, C. C., Ellis, K. A., Rimajova, M., Bourgeat, P., Pike, K. E., Jones, G., Fripp, J., Tochon-Danguy, H., Morandeau, L., O'Keefe, G., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.007 · Cited by 986 · cited 1×
“5 or 2 standard deviations higher than normal controls [34, 56, 103–105], while others used more complex approaches such as cluster analyses [12, 48, 106, 107], iterative outlier removal [108] or complex functions [94].”
MethodJack, C. R., Lowe, V. J., Senjem, M. L., Weigand, S. D., Kemp, B. J., Shiung, M. M., Knopman, D. S., Boeve, B. F., Klunk, W. E., Mathis, C. A., et al. (2008) · Brain · doi:10.1093/brain/awm336 · Cited by 958 · cited 1×
“5 or 2 standard deviations higher than normal controls [34, 56, 103–105], while others used more complex approaches such as cluster analyses [12, 48, 106, 107], iterative outlier removal [108] or complex functions [94].”
MethodThe neural basis of functional brain imaging signals
Attwell, D., & Iadecola, C. (2002) · Trends in Neurosciences · doi:10.1016/s0166-2236(02)02264-6 · Cited by 957
Brożek, J. L., Akl, E. A., Alonso‐Coello, P., Lang, D., Jaeschke, R., Williams, J. W., Phillips, B., Lelgemann, M., Lethaby, A., Bousquet, J., et al. (2009) · Allergy · doi:10.1111/j.1398-9995.2009.01973.x · Cited by 894
Clark, C. M., Pontecorvo, M. J., Beach, T. G., Bedell, B. J., Coleman, R. E., Doraiswamy, P. M., Fleisher, A. S., Reiman, E. M., Sabbagh, M. N., Sadowsky, C. H., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70142-4 · Cited by 855
Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET
Herholz, K., Salmon, E., Perani, D., Baron, J.-C., Holthoff, V., Frölich, L., Schönknecht, P., Ito, K., Mielke, R., & Kalbe, E. (2002) · NeuroImage · doi:10.1006/nimg.2002.1208 · Cited by 832 · cited 1×
“For example, FDG-PET can be assessed using software that analyses the pattern of tracer uptake voxel-wise by comparing the subject’s scan with a reference data set of normal ageing, allowing a better recognition of the patterns of hypometabolism compared with visual interpretation [15, 17, 27].”
MethodSelf-citationMosconi, L., Tsui, W. H., Herholz, K., Pupi, A., Drzezga, A., Lucignani, G., Reiman, E. M., Holthoff, V., Kalbe, E., Sorbi, S., et al. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.045385 · Cited by 726 · cited 1×
“Mosconi and colleagues [89], in a large multicenter study, examined FDG-PET measures in the differentiation of AD, FTD, and DLB from normal aging and from each other (N = 548 subjects, including 111 healthy individuals).”
BackgroundMcKeith, I., O'Brien, J., Walker, Z., Tatsch, K., Booij, J., Darcourt, J., Padovani, A., Giubbini, R., Bonuccelli, U., Volterrani, D., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70057-1 · Cited by 716
Self-citationde Leon, M. J., Convit, A., Wolf, O. T., Tarshish, C. Y., DeSanti, S., Rusinek, H., Tsui, W., Kandil, E., Scherer, A. J., Roche, A., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191044198 · Cited by 629
Comparing predictors of conversion and decline in mild cognitive impairment
Landau, S. M., Harvey, D., Madison, C. M., Reiman, E. M., Foster, N. L., Aisen, P. S., Petersen, R. C., Shaw, L. M., Trojanowski, J. Q., Jack, C. R., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181e8e8b8 · Cited by 616 · cited 1×
“Recently, Landau and coworkers [85] compared different biomarkers of conversion and decline in MCI investigating a fairly large cohort throughout the different predictors (FDGPET, MRI/hippocampal volume, CSF biomarkers, Memory”
BackgroundFDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease
Foster, N. L., Heidebrink, J. L., Clark, C. M., Jagust, W. J., Arnold, S. E., Barbas, N. R., DeCarli, C. S., Scott Turner, R., Koeppe, R. A., Higdon, R., et al. (2007) · Brain · doi:10.1093/brain/awm177 · Cited by 608 · cited 2×
“Despite the potential of visual inspection, modern techniques for quantification of FDG uptake are now widely used, and have been demonstrated to improve diagnosis accuracy and readability of hypometabolism patterns [33].”
BackgroundResultMinoshima, S., Foster, N. L., Sima, A. A. F., Frey, K. A., Albin, R. L., & Kuhl, D. E. (2001) · Annals of Neurology · doi:10.1002/ana.1133 · Cited by 560 · cited 3×
“[42] examined brain glucose metabolism of DLB and AD and showed that FDG-PET discriminates DLB from AD with 90% sensitivity and 80% specificity using autopsy confirmation.”
BackgroundMethodHippocampal formation glucose metabolism and volume losses in MCI and AD
De Santi, S., de Leon, M. J., Rusinek, H., Convit, A., Tarshish, C. Y., Roche, A., Tsui, W. H., Kandil, E., Boppana, M., Daisley, K., et al. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00230-5 · Cited by 548 · cited 1×
“Hypometabolism in AD has showed a very peculiar pattern since the emergence of early PET evidences [37, 38] recently defined in detail as involving parietal and temporal regions, precuneus, posterior cingulate cortex, medial temporal cortex, and structures (like hippocampus) [10, 14, 39–41].”
BackgroundMosconi, L., Mistur, R., Switalski, R., Tsui, W. H., Glodzik, L., Li, Y., Pirraglia, E., De Santi, S., Reisberg, B., Wisniewski, T., et al. (2009) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-008-1039-z · Cited by 487
Relationships between biomarkers in aging and dementia
Jagust, W. J., Landau, S. M., Shaw, L. M., Trojanowski, J. Q., Koeppe, R. A., Reiman, E. M., Foster, N. L., Petersen, R. C., Weiner, M. W., Price, J. C., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181bc010c · Cited by 456 · cited 1×
“, [72] for (11)C-PIB PET or [73] for (18)F-Florbetapir).”
BackgroundRelationship between atrophy and β‐amyloid deposition in Alzheimer disease
Chételat, G., Villemagne, V. L., Bourgeat, P., Pike, K. E., Jones, G., Ames, D., Ellis, K. A., Szoeke, C., Martins, R. N., O'Keefe, G. J., et al. (2010) · Annals of Neurology · doi:10.1002/ana.21955 · Cited by 373
Johnson, K. A., Minoshima, S., Bohnen, N. I., Donohoe, K. J., Foster, N. L., Herscovitch, P., Karlawish, J. H., Rowe, C. C., Carrillo, M. C., Hartley, D. M., et al. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.120618 · Cited by 329
Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD
Rabinovici, G. D., Rosen, H. J., Alkalay, A., Kornak, J., Furst, A. J., Agarwal, N., Mormino, E. C., O'Neil, J. P., Janabi, M., Karydas, A., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31823b9c5e · Cited by 318 · cited 1×
“Similarly, [34] demonstrated the higher sensitivity of (11)CPiB BP analysis in discriminating AD from FTD patients.”
BackgroundPIB is a non-specific imaging marker of amyloid-beta (A ) peptide-related cerebral amyloidosis
Lockhart, A., Lamb, J. R., Osredkar, T., Sue, L. I., Joyce, J. N., Ye, L., Libri, V., Leppert, D., & Beach, T. G. (2007) · Brain · doi:10.1093/brain/awm191 · Cited by 302
Arnáiz, E., Jelic, V., Almkvist, O., Wahlund, L.-O., Winblad, B., Valind, S., & Nordberg, A. (2001) · Neuroreport · doi:10.1097/00001756-200103260-00045 · Cited by 302
Grimmer, T., Riemenschneider, M., Förstl, H., Henriksen, G., Klunk, W. E., Mathis, C. A., Shiga, T., Wester, H.-J., Kurz, A., & Drzezga, A. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.01.027 · Cited by 278 · cited 1×
“Further, at least in AD, brain amyloid deposition seems to be a very early phenomenon and rather rapidly reaches a “plateau” at the time cognitive deficits become detectable [123], thus mirroring Aβ 1–42 levels in cerebrospinal fluid [124].”
BackgroundBrożek, J. L., Akl, E. A., Jaeschke, R., Lang, D. M., Bossuyt, P., Glasziou, P., Helfand, M., Ueffing, E., Alonso‐Coello, P., Meerpohl, J., et al. (2009) · Allergy · doi:10.1111/j.1398-9995.2009.02083.x · Cited by 270 · cited 1×
“Available scientific evidence regarding each of the topics was graded in terms of level of confidence (LoC: VL = very low, L = low, M = moderate, and H = high), as reported by the GRADE collaboration [74, 75].”
BackgroundLeinonen, V. (2008) · Archives of Neurology · doi:10.1001/archneur.65.10.noc80013 · Cited by 199
Amyloid PET imaging in patients with mild cognitive impairment: A 2-year follow-up study
Koivunen, J., Scheinin, N., Virta, J. R., Aalto, S., Vahlberg, T., Någren, K., Helin, S., Parkkola, R., Viitanen, M., & Rinne, J. O. (2011) · Neurology · doi:10.1212/wnl.0b013e318212015e · Cited by 188 · cited 2×
“Other amyloid-PET studies addressing AD and MCI cases in large series came out in the literature reporting high sensitivity and intermediate/low values of specificity [21, 46, 62, 100, 101].”
BackgroundA European multicentre PET study of fibrillar amyloid in Alzheimer’s disease
Nordberg, A., Carter, S. F., Rinne, J., Drzezga, A., Brooks, D. J., Vandenberghe, R., Perani, D., Forsberg, A., Långström, B., Scheinin, N., et al. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2237-2 · Cited by 186 · cited 2×
“[22] in a European multicentre PET study of fibrillar amyloid in AD based on very large”
BackgroundSelf-citationPrediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease
Prestia, A., Caroli, A., van der Flier, W. M., Ossenkoppele, R., Van Berckel, B., Barkhof, F., Teunissen, C. E., Wall, A. E., Carter, S. F., Schöll, M., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e3182872830 · Cited by 184 · cited 1×
“Review Article”
Self-citationMormino, E. C., Brandel, M. G., Madison, C. M., Rabinovici, G. D., Marks, S., Baker, S. L., & Jagust, W. J. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2011.07.098 · Cited by 158 · cited 2×
“A similar result has been described more recently by Mormino and coworkers [108] who found that the 15% of a large cohort of elderly”
MethodResultWolk, D. A. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.153 · Cited by 156
Research works printed but not linked: 98
- 10.1212/01.wnl.0000269790.05105.16 · DOI · Paper page
- 10.1002/mds.23291 · DOI · Paper page
- 10.1111/j.1749-6632.2011.06015.x · DOI · Paper page
- 10.1111/j.1749-6632.2011.06025.x · DOI
- 10.1016/j.jalz.2011.03.008 · DOI · Paper page
- 10.1016/j.jalz.2011.03.005 · DOI · Paper page
- 10.1016/j.jalz.2011.03.003 · DOI · Paper page
- 10.1016/S1474-4422(07)70178-3 · DOI · Paper page
- 2001, Journal of the American Medical Association, 286, 2120, 10.1001/jama.286.17.2120 · DOI · Paper page
- 10.1007/s12035-008-8019-y · DOI
- 10.2967/jnumed.111.089730 · DOI · Paper page
- 10.1006/nimg.1998.0381 · DOI · Paper page
- 1995, Journal of Nuclear Medicine, 36, 1238
- 10.2967/jnumed.111.094946 · DOI · Paper page
- 10.2967/jnumed.111.096578 · DOI · Paper page
- 10.1001/archneur.62.11.1728 · DOI · Paper page
- 10.3174/ajnr.A1357 · DOI · Paper page
- 10.1212/WNL.0b013e3181b23564 · DOI · Paper page
- 10.1016/j.jalz.2010.06.004 · DOI · Paper page
- 10.2967/jnumed.106.037762 · DOI · Paper page
- 10.1016/j.neuroimage.2013.01.015 · DOI · Paper page
- 10.1016/j.neuroimage.2009.06.079 · DOI
- 10.1007/s00259-011-2021-8 · DOI · Paper page
- 10.1001/archneurol.2008.511 · DOI · Paper page
- 10.1212/WNL.0b013e318246d67a · DOI · Paper page
- 2012, The New England Journal of Medicine, 367
- 10.4061/2011/946590 · DOI
- 1983, Journal of Cerebral Blood Flow and Metabolism, 3, 391, 10.1038/jcbfm.1983.57 · DOI · Paper page
- 1984, Radiology, 150, 625, 10.1148/radiology.150.3.6607481 · DOI
- 10.1007/s00259-005-1762-7 · DOI · Paper page
- 10.1007/s00259-009-1218-6 · DOI
- 10.1148/radiol.12120010 · DOI · Paper page
- 10.1016/j.neuroimage.2010.10.081 · DOI · Paper page
- 10.1016/S1474-4422(09)70299-6 · DOI · Paper page
- 10.3174/ajnr.A1809 · DOI · Paper page
- 10.1002/path.2885 · DOI · Paper page
- 10.2967/jnumed.110.076315 · DOI · Paper page
- 10.1016/S0960-894X(01)00734-X · DOI · Paper page
- 10.1002/ana.20009 · DOI · Paper page
- 10.2967/jnumed.108.058529 · DOI · Paper page
- 10.1177/0891988710363715 · DOI · Paper page
- 10.2967/jnumed.110.083683 · DOI
- 10.2967/jnumed.110.082057 · DOI
- 10.1016/j.neurobiolaging.2010.06.015 · DOI
- 10.1002/ana.21345 · DOI · Paper page
- 10.1016/j.neurobiolaging.2007.03.029 · DOI · Paper page
- 2005, Journal of Nuclear Medicine, 46, 1959
- 10.1016/j.neuroimage.2010.12.070 · DOI · Paper page
- 10.2967/jnumed.111.095927 · DOI
- 10.1016/j.neuroimage.2012.01.099 · DOI · Paper page
- 10.1053/j.semnuclmed.2011.02.005 · DOI
- 10.1016/S1474-4422(11)70123-5 · DOI · Paper page
- 10.1001/archneurol.2011.150 · DOI · Paper page
- 10.2967/jnumed.112.109009 · DOI · Paper page
- 10.2967/jnumed.111.090340 · DOI · Paper page
- 10.1186/1748-5908-6-62 · DOI · Paper page
- 2011, Chinese Journal of Evidence-Based Medicine, 11, 1444
- 10.1016/S1474-4422(12)70305-8 · DOI
- 2004, Neurology, 63, 2332, 10.1212/01.WNL.0000147469.18313.3B · DOI · Paper page
- 1988, Journal of Consulting and Clinical Psychology, 56, 123, 10.1037/0022-006X.56.1.123 · DOI · Paper page
- 2005, Journal of Nuclear Medicine, 46, 1625
- 10.1007/s00259-004-1576-z · DOI
- 10.1159/000241879 · DOI · Paper page
- 10.1007/s00259-013-2478-8 · DOI
- 10.1007/s00259-013-2458-z · DOI
- 10.1016/j.expneurol.2004.06.017 · DOI
- 10.1016/S0006-8993(00)02945-0 · DOI · Paper page
- 10.1038/nrneurol.2012.81 · DOI
- 10.1016/S1474-4422(08)70001-2 · DOI · Paper page
- 10.1002/ana.22068 · DOI · Paper page
- 10.1016/S1474-4422(11)70077-1 · DOI · Paper page
- 10.1007/s00259-011-1821-1 · DOI
- 10.1007/s00259-012-2088-x · DOI · Paper page
- 10.2967/jnumed.112.107185 · DOI
- 10.2174/156720510790274446 · DOI · Paper page
- 10.1002/ana.21598 · DOI · Paper page
- 10.1016/j.bbadis.2011.11.006 · DOI
- 10.1159/000318754 · DOI
- 10.1016/j.jns.2009.06.005 · DOI
- 10.1016/j.jalz.2010.03.003 · DOI · Paper page
- 10.1212/WNL.78.1_MeetingAbstracts.P03.106 · doi:10.1212/wnl.78.1_meetingabstracts.p03.106
- 10.1136/jnnp.74.10.1371 · DOI · Paper page
- 10.1073/pnas.0500579102 · DOI · Paper page
- 2005, Journal of Nuclear Medicine, 46, 233
- 10.1016/S1053-8119(03)00346-X · DOI
- 10.1016/j.bandl.2004.11.007 · DOI
- 1999, Archives of Neurology, 56, 303, 10.1001/archneur.56.3.303 · DOI · Paper page
- 2001, Archives of Neurology, 58, 1985, 10.1001/archneur.58.12.1985 · DOI · Paper page
- 10.1002/mds.22581 · DOI · Paper page
- 10.3233/JAD-2011-0020 · DOI
- 10.1093/brain/awl178 · DOI · Paper page
- 10.1093/brain/aws125 · DOI · Paper page
- 2012, The Lancet Neurology, 11, 1057, 10.1016/S1474-4422(12)70227-2 · DOI · Paper page
- 2013, The Lancet Neurology, 12, 357, 10.1016/S1474-4422(13)70044-9 · DOI · Paper page
- 10.1002/ana.10161 · DOI · Paper page
- 10.1212/WNL.0b013e318232ac1a · DOI · Paper page
- 10.1007/s12149-009-0330-9 · DOI
- 10.1016/j.jalz.2013.06.001 · DOI · Paper page
Cited by
Glucose Transporters at the Blood-Brain Barrier: Function, Regulation and Gateways for Drug Delivery
Patching, S. G. (2017) · Molecular Neurobiology · doi:10.1007/s12035-015-9672-6 · Cited by 361
Quantification of amyloid PET for future clinical use: a state-of-the-art review
Pemberton, H. G., Collij, L. E., Heeman, F., Bollack, A., Shekari, M., Salvadó, G., Alves, I. L., Garcia, D. V., Battle, M., Buckley, C., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05784-y · Cited by 226
Brain glucose metabolism in Lewy body dementia: implications for diagnostic criteria
Caminiti, S. P., Sala, A., Iaccarino, L., Beretta, L., Pilotto, A., Gianolli, L., Iannaccone, S., Magnani, G., Padovani, A., Ferini-Strambi, L., et al. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0473-4 · Cited by 86
Self-citationUnified theory of Alzheimer’s disease (UTAD): implications for prevention and curative therapy
Nehls, M. (2016) · Journal of Molecular Psychiatry · doi:10.1186/s40303-016-0018-8 · Cited by 41
Ito, K., Sasaki, M., Takahashi, J., Uwano, I., Yamashita, F., Higuchi, S., Goodwin, J., Harada, T., Kudo, K., & Terayama, Y. (2015) · Psychiatry Research: Neuroimaging · doi:10.1016/j.pscychresns.2015.01.020 · Cited by 26
Metadata
- Authors
- Daniela, P., Orazio, S., Alessandro, P., Mariano, N. F., Leonardo, I., Pasquale Anthony, D. R., Giovanni, F., & Carlo, C.
- Venue
- BioMed Research International
- Publisher
- Wiley
- Published
- 2014
- Volume
- 2014
- Pages
- 1-22
- ISSN
- 1110-7243 (ISSN-L)
- 2314-6133
- 2314-6141
- OpenAlex
- W1993217119
- Cited by
- 58
- References
- 38
- FWCI
- 5.61
- Type
- journal article
- Language
- en
- Update notices
- erratum (2014-06-11)
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.